 "Glenmark Pharma Q1 net up 44% at Rs 184.8 crore")
The company had posted net profit of Rs 128.6 crore in the same quarter of the previous year.
Consolidated net sales of the company rose by 19.38% to Rs 1,477.8 crore during the quarter under review, as against Rs 1,237.8 crore in the same period of previous fiscal, Glenmark Pharma said in a BSE filing.
Also Read
"We have delivered strong results backed by good performances by our India, Rest of the World, Europe and LATAM (Latin America) businesses. While we outperformed in the Indian Pharmaceutical market with a growth of over 20%," company's Chairman and MD Glenn Saldanha said.
"We have been making steady progress in our innovation pipeline and now have three first-in-class monoclonal antibodies in clinical development," he added.
The company's India business grew by 20.87% to Rs 397.1 crore while US business grew by 9.33% to Rs 488.6 crore.
Its rest of the world (ROW) business grew by 20.67% to Rs 211.3 crore.
Glenmark scrip closed at Rs 596.25, up 0.78% from its previous close on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%